Drug Metabolism Reviews最新文献_第6页

Clinical pharmacokinetics of nebivolol: a systematic review. 奈比洛尔的临床药代动力学：系统综述。

IF 3.4 2区医学

Drug Metabolism Reviews Pub Date : 2023-11-01 Epub Date: 2023-10-28 DOI: 10.1080/03602532.2023.2271195

Nida Hanif, Ammara Zamir, Imran Imran, Hamid Saeed, Abdul Majeed, Anees Ur Rehman, Waseem Ashraf, Faleh Alqahtani, Muhammad Fawad Rasool

{"title":"Clinical pharmacokinetics of nebivolol: a systematic review.","authors":"Nida Hanif, Ammara Zamir, Imran Imran, Hamid Saeed, Abdul Majeed, Anees Ur Rehman, Waseem Ashraf, Faleh Alqahtani, Muhammad Fawad Rasool","doi":"10.1080/03602532.2023.2271195","DOIUrl":"10.1080/03602532.2023.2271195","url":null,"abstract":"Nebivolol is a beta-1 receptor blocker used to treat hypertension, heart failure, erectile dysfunction, vascular disease, and diabetes mellitus. This review investigated the data regarding pharmacokinetic (PK) parameters, drug-drug interactions, dextrorotatory (D), and levorotatory (L) stereoisomers of nebivolol. The articles related to the PK of nebivolol were retrieved by searching the five databases; Google Scholar, PubMed, Cochrane Library, ScienceDirect, and EBSCO. A total of 20 studies comprising plasma concentration-time profile data following the nebivolol's oral and intravenous (IV) administration were included. The area under the concentration-time curve from zero to infinity (AUC0-∞) was 15 times greater in poor metabolizers (PMs) than in extensive metabolizers (EMs). In hypertensive patients, L-nebivolol expressed a higher maximum plasma concentration (Cmax) than D-nebivolol, i.e. 2.5 ng/ml vs 1.2 ng/ml. The AUC0-∞ of nebivolol was 3-fold greater in chronic kidney disease (CKD). The clearance (CL) was increased in obese than in controls from 51.6 ± 11.6 L/h to 71.6 ± 17.4 L/h when 0.5 mg/ml IV solution was infused. Nebivolol showed higher Cmax, AUC0-∞ and half-life (t1/2) when co-administered with bupropion, duloxetine, fluvoxamine, paroxetine, lansoprazole, and fluoxetine. This concise review of nebivolol would be advantageous in assessing all PK parameters, which may be crucial for clinicians to avoid drug-drug interactions, prevent adverse drug events and optimize the dosage regimen in diseased patients diagnosed with hypertension and cardiovascular disorders.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":" ","pages":"428-440"},"PeriodicalIF":3.4,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41233275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pregnane X receptor as a therapeutic target for cholestatic liver injury. 妊娠X受体作为胆汁淤积性肝损伤的治疗靶点。

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-11-01 Epub Date: 2023-09-10 DOI: 10.1080/03602532.2023.2248680

Huan Lan, Ying Zhang, Minqi Fan, Bingxin Wu, Caiyan Wang

引用次数: 0

Differential modulation of cytochrome P450 enzymes by arsenicals in non-human experimental models. 非人类实验模型中砷对细胞色素P450酶的差异调节。

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-11-01 Epub Date: 2023-09-07 DOI: 10.1080/03602532.2023.2254525

Mahmoud A El-Ghiaty, Sara R El-Mahrouk, Mohammed A Alqahtani, Ayman O S El-Kadi

引用次数: 0

Interaction of drugs with gut microbiota modulators. 药物与肠道菌群调节剂的相互作用。

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-08-01 DOI: 10.1080/03602532.2023.2197178

Dong-Hyun Kim

引用次数: 0

Antitubercular drugs induced liver injury: an updated insight into molecular mechanisms. 抗结核药物诱导肝损伤:对分子机制的最新见解。

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-08-01 DOI: 10.1080/03602532.2023.2215478

Devaraj Ezhilarasan

{"title":"Antitubercular drugs induced liver injury: an updated insight into molecular mechanisms.","authors":"Devaraj Ezhilarasan","doi":"10.1080/03602532.2023.2215478","DOIUrl":"https://doi.org/10.1080/03602532.2023.2215478","url":null,"abstract":"Tuberculosis (TB) remains a major global health burden. Antitubercular drugs (ATDs) such as isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol are used as first-line therapy in TB patients. Drug-induced liver injury is one of the common side effects that leads to the discontinuation of ATDs in TB patients. Therefore, this review discusses the molecular pathogenesis of ATDs induced liver injury. The biotransformation of INH, RIF, and PZA in the liver liberates several reactive intermediates, leading to peroxidation of the hepatocellular membrane and oxidative stress. INH + RIF administration decreased the expression of bile acid transporters such as the bile salt export pump and multidrug resistance-associated protein 2 and induced liver injury by sirtuin 1 and farnesoid X receptor pathway. INH inhibits the nuclear translocation of Nrf2 by interfering with its nuclear importer, karyopherin β1, thereby inducing apoptosis. INF + RIF treatments alter Bcl-2 and Bax homeostasis, mitochondrial membrane potential, and cytochrome c release, thereby triggering apoptosis. RIF administration enhances the expression of genes involved in fatty acid synthesis and hepatocyte fatty acid uptake (CD36). RIF induces the expression of peroxisome proliferator-activated receptor -γ and its downstream proteins and perilipin-2 by activating the pregnane X receptor in the liver to increase fatty infiltration into the liver. ATDs administration induces oxidative stress, inflammation, apoptosis, cholestasis, and lipid accumulation in the liver. However, ATDs toxic potentials are not elaborately studied at the molecular level in clinical samples. Therefore, future studies are warranted to explore ATDs induced liver injuries at the molecular level in clinical samples whenever possible.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":"55 3","pages":"239-253"},"PeriodicalIF":5.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9882324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bufalin serves as a pharmaceutic that mitigates drug resistance. 蟾毒灵是一种减轻耐药性的药物。

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-08-01 DOI: 10.1080/03602532.2023.2206065

Linxuan Miao, Ying Liu, Nasra Mohamoud Ali, Yan Dong, Bin Zhang, Xiaonan Cui

引用次数: 2

Plasma protein-mediated uptake and contradictions to the free drug hypothesis: a critical review. 血浆蛋白介导的摄取和游离药物假说的矛盾:一个重要的回顾。

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-08-01 DOI: 10.1080/03602532.2023.2195133

Julia Annette Schulz, David M Stresser, John Cory Kalvass

{"title":"Plasma protein-mediated uptake and contradictions to the free drug hypothesis: a critical review.","authors":"Julia Annette Schulz, David M Stresser, John Cory Kalvass","doi":"10.1080/03602532.2023.2195133","DOIUrl":"https://doi.org/10.1080/03602532.2023.2195133","url":null,"abstract":"According to the free drug hypothesis (FDH), only free, unbound drug is available to interact with biological targets. This hypothesis is the fundamental principle that continues to explain the vast majority of all pharmacokinetic and pharmacodynamic processes. Under the FDH, the free drug concentration at the target site is considered the driver of pharmacodynamic activity and pharmacokinetic processes. However, deviations from the FDH are observed in hepatic uptake and clearance predictions, where observed unbound intrinsic hepatic clearance (CLint,u) is larger than expected. Such deviations are commonly observed when plasma proteins are present and form the basis of the so-called plasma protein-mediated uptake effect (PMUE). This review will discuss the basis of plasma protein binding as it pertains to hepatic clearance based on the FDH, as well as several hypotheses that may explain the underlying mechanisms of PMUE. Notably, some, but not all, potential mechanisms remained aligned with the FDH. Finally, we will outline possible experimental strategies to elucidate PMUE mechanisms. Understanding the mechanisms of PMUE and its potential contribution to clearance underprediction is vital to improving the drug development process.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":"55 3","pages":"205-238"},"PeriodicalIF":5.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10249197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The alteration of drug metabolism enzymes and pharmacokinetic parameters in nonalcoholic fatty liver disease: current animal models and clinical practice. 非酒精性脂肪性肝病中药物代谢酶和药代动力学参数的改变:目前的动物模型和临床实践

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-08-01 DOI: 10.1080/03602532.2023.2202359

Yan Zhu, Li Chen, Yuqi He, Lin Qin, Daopeng Tan, Zhaojun Bai, Yu Song, Yuhe Wang

{"title":"The alteration of drug metabolism enzymes and pharmacokinetic parameters in nonalcoholic fatty liver disease: current animal models and clinical practice.","authors":"Yan Zhu, Li Chen, Yuqi He, Lin Qin, Daopeng Tan, Zhaojun Bai, Yu Song, Yuhe Wang","doi":"10.1080/03602532.2023.2202359","DOIUrl":"https://doi.org/10.1080/03602532.2023.2202359","url":null,"abstract":"Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease. The whole concept of NAFLD has now moved into metabolic dysfunction-associated fatty liver disease (MAFLD) to emphasize the strong metabolic derangement as the basis of the disease. Several studies have suggested that hepatic gene expression was altered in NAFLD and NAFLD-related metabolic comorbidities, particularly mRNA and protein expression of phase I and II drug metabolism enzymes (DMEs). NAFLD may affect the pharmacokinetic parameters. However, there were a limited number of pharmacokinetic studies on NAFLD at present. Determining the pharmacokinetic variation in patients with NAFLD remains challenging. Common modalities for modeling NAFLD included: dietary induction, chemical induction, or genetic models. The altered expression of DMEs has been found in rodent and human samples with NAFLD and NAFLD-related metabolic comorbidities. We summarized the pharmacokinetic changes of clozapine (CYP1A2 substrate), caffeine (CYP1A2 substrate), omeprazole (Cyp2c29/CYP2C19 substrate), chlorzoxazone (CYP2E1 substrate), midazolam (Cyp3a11/CYP3A4 substrate) in NAFLD. These results led us to wonder whether current drug dosage recommendations may need to be reevaluated. More objective and rigorous studies are required to confirm these pharmacokinetic changes. We have also summarized the substrates of the DMEs aforementioned. In conclusion, DMEs play an important role in the metabolism of drugs. We hope that future investigations should focus on the effect and alteration of DMEs and pharmacokinetic parameters in this special patient population with NAFLD.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":"55 3","pages":"163-180"},"PeriodicalIF":5.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9881794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Physiological and pathophysiological roles of hepoxilins and their analogs. 血红素及其类似物的生理和病理生理作用。

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-08-01 DOI: 10.1080/03602532.2023.2219035

Sara A Helal, Fadumo Ahmed Isse, Samar H Gerges, Ayman O S El-Kadi

{"title":"Physiological and pathophysiological roles of hepoxilins and their analogs.","authors":"Sara A Helal, Fadumo Ahmed Isse, Samar H Gerges, Ayman O S El-Kadi","doi":"10.1080/03602532.2023.2219035","DOIUrl":"https://doi.org/10.1080/03602532.2023.2219035","url":null,"abstract":"The metabolism of arachidonic acid (AA) occurs via different pathways leading to the production of a great number of metabolites with a wide range of biological effects. Hepoxilins (HXs) are physiologically active AA metabolites produced through the lipoxygenase pathway. Since their discovery, several researchers have investigated their biological effects. They were proven to have pro-inflammatory, anti-apoptotic, and skin-protective effects. HXs also contribute to the processes of neutrophil activation and migration and inflammatory hyperalgesia. The major limitation to their effects is that they are highly labile and are metabolized into less active compounds which led to the synthesis of stable HXs analogs called proprietary bioactive therapeutics (PBTs). Although PBTs were synthesized to further study the effect of HXs, they showed different effects than natural HXs under some conditions. PBTs were proven to have anti-inflammatory and anti-cancer effects and were found to be potent antagonists of the thromboxane receptor. In this review article, we aimed to provide an overview of some physiological and pathophysiological effects of hepoxilins and their analogs on the skin, platelet, blood vessel, neutrophil, and cell survival.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":"55 3","pages":"254-266"},"PeriodicalIF":5.9,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10274610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of intestinal flora on pharmacokinetics and pharmacodynamics of drugs. 肠道菌群对药物药代动力学和药效学的影响。

IF 5.9 2区医学

Drug Metabolism Reviews Pub Date : 2023-02-01 DOI: 10.1080/03602532.2023.2186313

Amina Džidić-Krivić, Jasna Kusturica, Emina Karahmet Sher, Nejra Selak, Nejra Osmančević, Esma Karahmet Farhat, Farooq Sher

{"title":"Effects of intestinal flora on pharmacokinetics and pharmacodynamics of drugs.","authors":"Amina Džidić-Krivić, Jasna Kusturica, Emina Karahmet Sher, Nejra Selak, Nejra Osmančević, Esma Karahmet Farhat, Farooq Sher","doi":"10.1080/03602532.2023.2186313","DOIUrl":"https://doi.org/10.1080/03602532.2023.2186313","url":null,"abstract":"Gut microbiota is known as unique collection of microorganisms (including bacteria, archaea, eukaryotes and viruses) that exist in a complex environment of the gut. Recently, this has become one of the most popular areas of research in medicine because this plays not only an important role in disease development, but gut microbiota also influences drug pharmacokinetics. These alterations in drug pharmacokinetic pathways and drug concentration in plasma and blood often lead to an increase in the incidence of toxicological events in patients. This review aims to present current knowledge of the most commonly used drugs in clinical practice and their dynamic interplay with the host's gut microbiota as well as the mechanisms underlying these metabolic processes and the consequent effect on their therapeutic efficacy and safety. These new findings set a foundation for the development of personalized treatments specific to each metabolism, maximizing drugs' therapeutic effects and minimizing the side effects because they are one of the major limiting factors in treating patients.","PeriodicalId":11307,"journal":{"name":"Drug Metabolism Reviews","volume":"55 1-2","pages":"126-139"},"PeriodicalIF":5.9,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9501564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9